Skip to content
lifestyle.chroniccities.us
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Aclarion, Inc.
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
May 5, 2026
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
April 30, 2026
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
April 28, 2026
Aclarion Announces $2.5 Million Stock Repurchase Plan
April 22, 2026
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
April 16, 2026
Aclarion Receives Pinnacle Award for AI Innovation
April 14, 2026
Aclarion Announces Agreement with Weill Cornell Medicine
April 8, 2026
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
April 7, 2026
Aclarion Publishes 2026 Shareholder Letter from the Chairman
February 11, 2026
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
February 3, 2026
←
Previous Page
1
2